MDNA109

**MDNA109** is an engineered IL-2 Superkine developed by Medicenna Therapeutics, originating from Stanford University research. It exhibits up to 200-fold increased binding affinity to **IL-2 receptor beta (IL-2Rβ or CD122)** compared to wild-type IL-2, selectively activating effector T cells and natural killer (NK) cells while minimizing stimulation of immunosuppressive regulatory T cells (Tregs). This bias enhances anti-tumor immune responses with reduced toxicity. Preclinical studies demonstrate synergy with checkpoint inhibitors like PD-1 inhibitors and potential for long-acting variants (e.g., MDNA109-LA) via fusions for extended half-life. It is in early development for cancer immunotherapy, targeting advanced solid tumors.

Other names

MDNA 109 FEAAMDNA109 FEAAMDNA-109 FEAA